Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: High utilization of drugs with interaction potential

Julie C. Lauffenburger, Christina L. Mayer, Roy L. Hawke, Kim L.R. Brouwer, Michael W. Fried, Joel F. Farley

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Background: With the advent of the direct-acting antiviral agents, significant drug-drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) infection. However, little is known about how often patients with HCV infection use medications that may interact with newer HCV treatments, especially those with cytochrome P450 3A (CYP3A) DDI potential. Methods: Using a large US commercial insurance database, medication use and comorbidity burden were examined among adult patients with a chronic HCV diagnosis from 2006 to 2010. Medications were examined in terms of total number of prescription claims, proportion of patients exposed, and DDI potential with the prototypical CYP3A direct-acting antiviral agents boceprevir and telaprevir, for which data were available. Results: Patient comorbidity burden was high and increased over the study period. Medication use was investigated in 53 461 patients with chronic HCV. Twentyone (53%) of the top 40 most utilized medications were classified as having interaction potential, with 62% of patients receiving at least one of the top 22 interacting medications by exposure. Of these, 59 and 41% were listed in a common DDI resource but not in medicationprescribing information, 77 and 77% had not been investigated in DDI studies, 41 and 36% did not have clear recommendations for DDI management, and only 14 and 23% carried a recommendation to avoid coadministration for boceprevir and telaprevir, respectively. Conclusion: Practitioners may expect a medication with CYP3A DDI potential in two-thirds of patients with HCV and may expect almost one-half of the most frequently used medications to have CYP3A DDI potential. However, DDI potential may not be reflected in prescribing information.

Original languageEnglish (US)
Pages (from-to)1073-1082
Number of pages10
JournalEuropean Journal of Gastroenterology and Hepatology
Volume26
Issue number10
DOIs
StatePublished - 2014

Bibliographical note

Publisher Copyright:
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Keywords

  • Boceprevir
  • Comorbidities
  • Drug interactions
  • Hepatitis C
  • Protease inhibitors
  • Telaprevir

Fingerprint

Dive into the research topics of 'Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: High utilization of drugs with interaction potential'. Together they form a unique fingerprint.

Cite this